Neuracle Science Co., Ltd.

Seoul National University

The Asan Foundation, University of Ulsan Foundation for Industry Cooperation

Junyeong Jin

Junho Chung

Bongcheol Kim

Jae-Keun Lee

Jae Young Seong

Hyori Kim

Jong Ik Hwang

Eun Bee Cho

Jee Youn Lee

Tae Young Yune

Wonkyum Kim

Jeongwon Yoon

Ji Eun Kim

Soohyun Kim

Dong Sik Kim

Jong Bae Park

Hwa Kyoung Lee

Eugene C Yi

Gunwoo Park

Eunhwoi You

ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof

The present invention relates to an anti-ROS1 antibody improved in specificity for ROS1 and a use thereof and, more particularly, provides an anti-ROS1 antibody or an antigen-binding fragment thereof and a use thereof in cancer diagnosis.

Anti-ROS1 antibody and use thereof

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.

Anti-FAM19A5 antibodies and uses thereof

The present invention relates to an antibody drug conjugate using a bispecific antibody and its use. The antibody drug conjugate of the present invention can easily form a conjugate of an antibody and a drug without a multistep synthetic process though binding of a conjugate of a bivalent cotinine-peptide and a drug, and an anti-cotinine single chain variable fragment. In addition, the antibody drug conjugate can effectively deliver a drug to a target to which the antibody binds specifically, and can enhance a half-life of a drug in the body, thereby improving a therapeutic effect.

Antibody drug conjugate platform using bispecific antibody

Growing community of inventors

Gwachun-si, South Korea

Junyeong Jin